Safety reporting requirements update

 

As most of our users have now formalised local governance processes for internal safety reporting, we have updated MAR G2 Safety reporting, to no longer require the submission of SUSARs for individual events at Bellberry sites.

To assist sites in understanding the updated requirements, if Bellberry's administrative team receives documentation not outlined in MAR G2, a reference will be made to MAR G2, and the submission returned.

General advice to sites regarding submissions:

If your study is multi-centre, please ensure your submission considers the participants at all centres.

For example:
•   There is a halt in recruitment due to drug supply issues in Australia. The Sponsor has confirmed there will be no supply for three weeks.

Example wording for the site submission:
Our site is awaiting governance sign off and has not recruited any participants. We will not recruit until the halt is lifted.
Dr Peters (site AA) has recruited one participant, and they have enough study drug to last their participant for 6 weeks. If there is any update to the supply issue that puts this participant at risk, we will notify the HREC.

•    If the urgent safety measure includes a request to inform participants of a safety issue:

Example wording for the site submission:
Our site has four active participants. Prof Barnes (site AA) has two participants. All were phoned and told of the safety event and documented in their notes. No participant had any further queries on the matter.

If your study includes a caveat and you are attaching documentation in relation to the caveat, please ensure your submission details the purpose of your attachments.

For example:
•    The caveat on the initial approval letter requests the following “Please submit correspondence from the DSMB during Part A of the trial. Part B cannot proceed until the HREC has reviewed the DSMB letters and an updated PICF and protocol is approved”.

Example wording for the site submission:
The attached DSMB letters refer to the caveat from the HREC on the initial approval letters that all correspondence must be submitted during Part A of the trial. Once the safety letters are acknowledged, the site will submit an amendment for Part B with an updated PICF and Protocol for HREC consideration.

The 'AER' safety reporting pathway questions will be updated in eProtocol in due course. Until then sites are welcome to select option 2, 'Summary report' for all submissions, as the relevant information regarding dates of events should exist in the attachments.

Please take the time to reflect on the updated reporting requirements and how this will impact your local procedures.

If you have any queries regarding these changes please contact Bellberry at bellberry@bellberry.com.au

Share this article:

Other articles

A blog for the latest news and articles related to the ethical review of human research from Bellberry Limited.

View all articles
Apr 30, 2026

Impact Report 2025

We’re proud to share Bellberry’s 2025 Impact Report - our first report bringing together key insights, data and achievements from the past…

Read More
Mar 25, 2026

Bellberry Office Easter Closure 2026

The Bellberry office will be closed for the Easter break on Friday 3 April and Monday 6 April. Reopening at 9am on…

Read More
Feb 17, 2026

2026 Podcast Season: More About NAMs

When a potential new medicine is tested on humans for the first time it is a milestone. It is thoroughly tested for…

Read More
Dec 23, 2025

Bellberry Newsletter – Summer 2025

Welcome to our newsletter for summer 2025. The Bell contains a roundup of the activities Bellberry has been involved with in the…

Read More
Dec 1, 2025

2025-26 Meeting & Submission Dates

Our end of year meeting and submission dates are as follows: The Bellberry office will be closed from COB Wed 24 December…

Read More
Dec 1, 2025

Project Officer Vacancy

Project Officer - Adelaide, Full time We're seeking a Project Officer with strong auditing and governance experience to help deliver services that…

Read More
Nov 12, 2025

2025/26 Bellberry-Viertel Fellow Announced

Last month at the Australian Academy of Health and Medical Sciences Gala Dinner in Canberra our new Bellberry-Viertel Fellow was announced! Congratulations…

Read More
Oct 30, 2025

2025-26 Meeting & Submission Dates

Our end of year meeting and submission dates are as follows: The Bellberry office will be closed from COB Wed 24 December…

Read More
Sep 30, 2025

National Statement Updates 2025

The National Statement on Ethical Conduct in Human Research is the principal reference for research involving humans in Australia and is the…

Read More
Sep 30, 2025

Operations Update 28

In the September issue of our Operations Update please find articles on: New Bellberry office address New eProtocol registrations contact email Bellberry…

Read More
Sep 30, 2025

Bellberry User Satisfaction Survey

As Australia’s largest provider of Human Research Ethics Committee services, Bellberry places great value on understanding the experience our users have of…

Read More
Sep 30, 2025

International Research Administrators Day

Today, September 25, we celebrate International Research Administrators Day! This globally recognised day honours the contribution of Research Administrators in supporting and…

Read More
Jun 12, 2025

NAMs workshop summary report released

We are pleased to release the summary report from the Bellberry & ASCEPT New Approach Methodologies (NAMs) Introductory Workshop, held in Melbourne,…

Read More
May 21, 2025

ACTA Trial of the Year Award Winner

On May 20, 2025, the Australian Clinical Trials Alliance (ACTA) hosted its annual Trial of the Year Awards, coinciding with International Clinical…

Read More
May 21, 2025

Clinical Trial Activity Report (CTAR) 2024

Report highlights international confidence in Australian clinical trials Global investment in Australian clinical trials is strong, with two thirds of Australian clinical…

Read More